PeptidesDirect

Easter Holiday Notice: Orders placed between April 3-13 will be shipped from April 14. Thank you for your patience!

Back to Blog
ResearchMarch 21, 2026

Mitochondrial Agents Compared: SS-31 vs MOTS-c vs NAD+

SS-31 (Elamipretide), MOTS-c and NAD+ in direct comparison. Mechanisms of action, evidence base and differences in research and clinical development.

Mitochondria regulate energy metabolism, influence apoptosis, control calcium homeostasis and generate reactive oxygen species (ROS) that also function as signalling molecules. As we age, mitochondrial function can decline. This is why mitochondrial targets have attracted growing attention in ageing and metabolic research over recent years.

Three of the most widely discussed agents in this context are SS-31 (Elamipretide), MOTS-c and NAD+. They each engage mitochondrial biology through very different mechanisms. SS-31 binds to structures of the inner mitochondrial membrane, MOTS-c is a mitochondrially encoded signalling molecule, and NAD+ is a coenzyme of energy metabolism - not a peptide.

This article compares the three compounds based on currently available evidence and clearly distinguishes between approved applications, clinical development and preclinical research.

Research Note

Elamipretide has been approved in the United States since 19 September 2025 as Forzinity for the treatment of Barth syndrome. MOTS-c and strategies to raise NAD+ remain the subject of ongoing research. The following information is intended for scientific orientation and does not constitute medical advice.

SS-31 (Elamipretide): Target Structure Inner Mitochondrial Membrane

SS-31, known in clinical development as Elamipretide, is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. It belongs to the class of Szeto-Schiller peptides and accumulates at the inner mitochondrial membrane.

Mechanism of Action

The best-characterised mechanism is binding to cardiolipin, a phospholipid of the inner mitochondrial membrane. Cardiolipin stabilises respiratory chain complexes and contributes to cristae architecture. Under oxidative stress, oxidised or functionally impaired cardiolipin may be associated with reduced efficiency of oxidative phosphorylation.

SS-31 is proposed to stabilise this membrane environment, thereby improving mitochondrial function under stress conditions. This mechanism is biologically plausible and supported by experimental work, though clinical efficacy is indication-dependent and not uniformly positive.

Evidence Base

On 19 September 2025, the FDA granted accelerated approval for Elamipretide under the brand name Forzinity for the treatment of Barth syndrome. The FDA documents also record priority review and rare pediatric disease designation. The approval was not communicated as a "Breakthrough Therapy" designation.

It is also important to characterise the evidence precisely: according to the FDA, the accelerated approval was supported by improvements in knee extensor muscle strength. A post-approval randomised, double-blind, placebo-controlled trial was required as a confirmatory study. The approval therefore did not rest solely on a single randomised crossover study at one centre.

For other indications, the picture is mixed:

  • Barth syndrome / TAZPOWER: There were clinical signals, but the six-minute walk test data are only interpretable in context. More pronounced effects were discussed primarily in extension and historical comparator data.
  • Geographic atrophy in AMD / ReCLAIM: ReCLAIM-2 did not meet its primary endpoints.
  • Heart failure / PROGRESS-HF: The phase 2 study found no significant improvement in LVESV or LVEF.
  • Primary mitochondrial myopathy / MMPOWER-3: The study missed its primary endpoints.
  • Further preclinical areas: Animal and laboratory work exists for ischaemia-reperfusion injury and other mitochondrial stress models, but does not establish clinical efficacy.

Regulatory Status

Elamipretide is currently most relevant for Barth syndrome, where an FDA approval exists. For other indications, the compound should continue to be regarded as clinically unconfirmed as long as negative or inconclusive studies have not been superseded by robust new data.

SS-31longevity

Mitochondria-targeted tetrapeptide (Elamipretide) that stabilizes cardiolipin and prevents ROS formation at the source.

MOTS-c: Mitochondrially Encoded Signalling Molecule

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA Type-c) differs fundamentally from SS-31. It is not a synthetic peptide but an endogenous, mitochondrially encoded peptide. It is derived from an open reading frame within the mitochondrial 12S rRNA and belongs to the mitochondrial-derived peptides (MDPs).

Mechanism of Action

MOTS-c is primarily associated with AMPK activation and changes in cellular energy metabolism. Described effects include influences on glucose uptake, fatty acid oxidation and the metabolic stress response.

Experimental work also suggests that under stress conditions MOTS-c can translocate to the cell nucleus and there influence gene expression programmes related to antioxidant response and metabolic regulation. These findings make MOTS-c an interesting signalling peptide - not a clinically validated therapeutic agent.

Evidence Base

Research into MOTS-c remains predominantly preclinical. Human studies are limited, and no approved medical application for MOTS-c itself currently exists.

  • Metabolic effects: In animal models, improvements in insulin sensitivity and glucose tolerance have been described.
  • Physical performance and ageing: Individual studies report declining MOTS-c levels with age and improvements in physical performance in aged animal models.
  • Stress and nuclear signalling: Cell and animal data support the hypothesis that MOTS-c acts as a retrograde signal between mitochondria and the cell nucleus.
  • Translation to humans: These data are mechanistically interesting but should not be equated with clinical proof of efficacy.

Genetic Variants

The MOTS-c variant m.1382A>C should not be characterised as a longevity variant without qualification. The available literature suggests it is not substantially involved in exceptional longevity. Associations discussed instead include muscle and performance phenotypes as well as a higher type 2 diabetes risk in physically inactive men.

MOTS-clongevity

Mitochondrial-derived signaling peptide (16 amino acids) that mimics the effects of exercise at the cellular level. Activates AMPK, improves glucose uptake, and enhances fat metabolism - a key tool in metabolic and longevity research.

NAD+: Coenzyme Rather Than Peptide

Nicotinamide adenine dinucleotide (NAD+) is not a peptide but a coenzyme involved in numerous redox reactions and regulatory pathways. It is relevant to mitochondrial function because it transports electrons and serves as a substrate for several enzyme families.

Mechanism of Action

NAD+ plays a central role particularly in three areas:

1. Sirtuins (SIRT1-7): NAD+-dependent enzymes that influence gene expression, mitochondrial metabolism and stress response, among other functions.

2. PARPs: DNA repair enzymes that consume NAD+. Higher levels of DNA damage can increase NAD+ consumption.

3. CD38/CD157: Enzymes that degrade NAD+ and are frequently discussed in ageing research as a factor contributing to altered NAD+ levels.

Evidence Base

The evidence base for NAD+ is broader than for MOTS-c, but less clear-cut in human research than marketing materials often suggest.

  • Preclinical data: For NAD+ precursors such as NMN and NR, effects on metabolism, mitochondrial function and resilience have been repeatedly described in animal models.
  • Human data: Studies in humans show primarily that certain precursors can influence NAD+-related markers in blood or individual tissues. Functional endpoints are considerably more inconsistent.
  • Ageing and NAD+ levels: Reviews emphasise that an age-associated decline in NAD+ in humans is likely tissue-specific and that the overall evidence remains limited and heterogeneous. The claim that human tissues generally lose up to 50 per cent of NAD+ between ages 40 and 60 is an oversimplification.
  • Clinical strategies: Current focus is on precursor molecules, on interventions targeting NAD+ degradation and on modulation of biosynthesis.

The study listed on ClinicalTrials.gov as NCT06882096 investigates according to its title the metabolic flux of orally administered NAD+ precursors. It should therefore not be described as a study of directly orally administered NAD+, but as a study of orally given NAD+ precursors.

NAD+ Precursors

Clinical research focuses primarily on NMN, NR and other precursors. Whether raising NAD+-related biomarkers in humans can be consistently translated into clinically relevant benefits remains an open question.

NAD+longevity

Essential cellular coenzyme that declines with age. Powers energy metabolism in every cell, activates sirtuins (longevity genes), and supports DNA repair. A cornerstone molecule in aging and longevity research.

Direct Comparison: SS-31 vs MOTS-c vs NAD+

The three compounds differ substantially in origin, target structure and maturity of evidence.

Point of Action

  • SS-31: Inner mitochondrial membrane and cardiolipin-associated membrane function
  • MOTS-c: Cellular stress and energy signalling pathways, particularly AMPK-related axes
  • NAD+: Redox metabolism and NAD+-dependent enzyme systems across multiple compartments

Origin

  • SS-31: Synthetic tetrapeptide
  • MOTS-c: Endogenous mitochondrial-derived peptide
  • NAD+: Endogenous coenzyme

Evidence Level

  • SS-31: FDA-approved for Barth syndrome; mixed to negative clinical data outside this indication
  • MOTS-c: Predominantly preclinical data with limited human translation
  • NAD+: Broad research field, clinically investigated mainly through precursors such as NMN and NR

Clinical Maturity

  • SS-31: Highest maturity among the three compared compounds, but indication-specific
  • MOTS-c: Early research stage
  • NAD+: Broad clinical exploration, but heterogeneous results and many unresolved questions

Combinations and Theoretical Synergies

At a mechanistic level, the three approaches can be described as distinct interventions in mitochondrial biology: SS-31 targets membrane stability, MOTS-c targets metabolic signalling, and NAD+ targets cofactor-dependent enzyme systems.

A theoretical synergistic potential can be derived from this. This is, however, primarily a conceptual consideration. No robust human studies currently exist demonstrating clinically meaningful combined effects of SS-31, MOTS-c and NAD+-related strategies.

In the broader context of longevity research, such mitochondrial approaches are frequently discussed alongside other strategies, such as Epitalon. This does not automatically imply a proven additional benefit in combination.

Epitalonlongevity

Tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase, the enzyme responsible for maintaining telomere length. One of the most studied peptides in longevity research, developed by Prof. Khavinson at the St. Petersburg Institute of Bioregulation.

Frequently Asked Questions

References

This article is intended solely for scientific information and orientation. It does not replace medical advice, diagnosis or therapeutic recommendations.